Track ACUT and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap-
Enterprise Value-
Revenue (TTM)-
Net Income (TTM)-$1.61M
Free Cash Flow (TTM)-$872.33K
Financial Health
Cash-
Net Debt-
Debt Ratio0
Debt to Equity-0
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings-
EV to EBITDA-
Price to Book-
Price to Free Cash Flow-
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-
Return on Assets-
Return on Equity-
Return on Total Capital-
Return on Capital Employed-
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (3Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (1Y)
Revenue0.00%
Diluted EPS-1.00%
Total Debt0.00%
Capital Expenditures0.00%
Free Cash Flow1000.00%
$0.20-$0.03|-10.87%
52W High$2.33
52W Low$0.16
50D SMA$0.23
200D SMA$0.57
Volume108.00
Accustem Sciences Inc
5 Penn Plaza, New York, NY, United States, 10001
IPO
-
Employees
4
Industry
Biotechnology
Sector
Healthcare
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available